

**LISTING OF THE CLAIMS**

This Listing of the Claims replaces all prior versions, and listings, of the claims for this application.

68. **(Currently Amended)** A topical pharmaceutical formulation for use in preventing or treating skin conditions, disorders and diseases associated with inflammation, comprising a topical carrier and a therapeutically effective concentration of an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs and analogs thereof, and combinations of any of the foregoing,

wherein the skin condition, disorder, or disease is selected from the group consisting of allergic contact dermatitis, atopic dermatitis, actinic keratosis, keratinization disorders, epidermolysis bullosa diseases, exfoliative dermatitis, seborrheic dermatitis, erythemas, discoid lupus erythematosus, dermatomyositis, and skin cancer.

69. **(Original)** The formulation of claim 68, wherein the active agent is *cis*-resveratrol or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof.

70. **(Original)** The formulation of claim 69, wherein the active agent is *cis*-resveratrol.

71. **(Original)** The formulation of claim 69, wherein the active agent is a conjugate of *cis*-resveratrol and a mono- or di-saccharide.

72. **(Original)** The formulation of claim 71, wherein the active agent is *cis*-resveratrol glucoside.

73. **(Original)** The formulation of claim 68, wherein the active agent is *trans*-resveratrol or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof.

74. **(Original)** The formulation of claim 73, wherein the active agent is *trans*-resveratrol.

75. **(Original)** The formulation of claim 74, wherein the active agent is a conjugate of *trans*-resveratrol and a mono- or di-saccharide.

76. (Original) The formulation of claim 75, wherein the active agent is *trans*-resveratrol glucoside.

77. (Original) The formulation of claim 68, wherein the active agent comprises a mixture of *cis*-resveratrol and *trans*-resveratrol.

78. (Original) The formulation of claim 68, wherein the topical carrier comprises an ointment base and the formulation is an ointment.

79. (Original) The formulation of claim 68, wherein the topical carrier comprises a cream base and the formulation is a cream.

*B*  
*cont.*  
80. (Original) The formulation of claim 68, wherein the topical carrier comprises a lotion base and the formulation is a lotion.

81. (Original) The formulation of claim 68, wherein the topical carrier comprises a gel base and the formulation is a gel.

82. (Original) The formulation of claim 68, wherein the topical carrier comprises an aqueous liquid and the formulation is a solution.

83. (Original) The formulation of claim 68, comprising a microemulsion.

84. (Original) The formulation of claim 68, comprising approximately 0.25 wt.% to 75 wt.% active agent.

85. (Original) The formulation of claim 84, comprising approximately 0.25 wt.% to 30 wt.% active agent.

86. (Original) The formulation of claim 85, comprising approximately 0.5 wt.% to 15 wt.% active agent.

87. (Original) The formulation of claim 86, comprising approximately 1.0 wt.% to 10 wt.% active agent.

88. (Currently Amended) A pharmaceutical formulation comprising:

approximately 0.25 wt.% to 30 wt.% of an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs and analogs thereof, and combinations of any of the foregoing;

approximately 2 wt.% to 20 wt.% emulsifiers;

approximately 2 wt.% to 20 wt.% emollient;

approximately 2 wt.% to 50 wt.% solubilizer;

approximately 0.1 wt.% to 0.2 wt.% preservative; and

water,

wherein said formulation is used for the treatment of skin conditions, disorders, or disease selected from the group consisting of allergic contact dermatitis, atopic dermatitis, actinic keratosis, keratinization disorders, epidermolysis bullosa diseases, exfoliative dermatitis, seborrheic dermatitis, erythemas, discoid lupus erythematosus, dermatomyositis, and skin cancer.

*B1  
cont.*

89. (Original) The formulation of claim 88, wherein the emulsifiers are selected from the group consisting of glyceryl monostearate, polyoxyethylene stearate, polyethylene glycol, ethylene glycol palmitostearate, caprylic/capric triglycerides, oleoyl macrogolglycerides, and combinations thereof.

90. (Original) The formulation of claim 88, wherein the emollient is selected from the group consisting of propylene glycol, glycerol, isopropyl myristate, PPG-2 ether propionate, and combinations thereof.

91. (Original) The formulation of claim 88, wherein the solubilizer is selected from the group consisting of diethylene glycol monoethyl ether, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether oleate, polyethylene glycol, polyethylene castor oil derivatives, PEG-8 caprylic/capric glycerides, alkyl methyl sulfoxides, pyrrolidones and dimethyl acetamide.

92. (New) A topical pharmaceutical formulation for inhibiting cellular events associated with tumor initiation, promotion, and progression, comprising a topical carrier and a therapeutically effective concentration of an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs and analogs thereof, and combinations of any of the foregoing.